Lixisenatide doesn't affect cardiovascular risk in T2DM
(HealthDay)—The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according ...
Dec 03, 2015
0
0